An International Non-Interventional Registry on the Quality of Life of Patients With Grass-pollen-induced Allergic Rhinitis Treated With Oralair®.
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Sponsor
- Stallergenes Greer
- Enrollment
- 740
- Locations
- 1
- Primary Endpoint
- Health related quality of life
Study Overview
Brief Summary
The purpose of the present study is to describe patient's perception of quality of life and effectiveness of ORALAIR® over a follow-up period up to 5 years, in real-life settings.
Detailed Description
Primary objective:
To describe the patient's perception of the impact of ORALAIR® on his/her health related generic and disease specific quality of life during the grass pollen season in real-life settings.
Secondary objectives:
- To describe the patient's perceived effectiveness of ORALAIR® in allergic rhinoconjunctivitis management in terms of disease intensity, satisfaction and rescue medication
Study Design
- Study Type
- Observational
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 5 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patient of 5 years of age and older at the date of the screening visit
- •Patient with proven allergic rhino-conjunctivitis due to grass pollen
- •Patient eligible for a grass-pollen Allergen ImmunoTherapy (AIT)
- •Patient whose physician prescribed ORALAIR® independently of the study, before the beginning of the grass-pollen season
Exclusion Criteria
- •Patient participating in a clinical trial or in an epidemiological study
Outcomes
Primary Outcomes
Health related quality of life
Time Frame: patients will be followed for the duration of the treatment, an expected average of 6 months/year
The primary objective is to describe the patient's perception of the impact of ORALAIR® on his/her health related generic and disease specific quality of life during the grass-pollen season in real-life settings.
Secondary Outcomes
- Treatment Effectiveness(patients will be followed for the duration of the treatment, an expected average of 6 months/year)